Novo aktie

2023 - 11 - 2

Post cover
Image courtesy of "Financial Times"

Novo Nordisk's sales of weight loss drugs soar (Financial Times)

Sales of the Danish pharmaceutical group's obesity and diabetes drugs soared 36 per cent to almost $22bn in the first nine months of the year, as patients ...

Post cover
Image courtesy of "Reuters"

Novo Nordisk to 'significantly' boost U.S. Wegovy doses next year (Reuters)

Novo Nordisk said on Thursday it will supply "significantly" more doses of Wegovy in the U.S. next year, even as it cautioned shortages of the weight-loss ...

Post cover
Image courtesy of "Forbes"

Ozempic Sales Up 58% As Drugmaker Novo Nordisk Nets Record ... (Forbes)

Revenue for the Danish company behind the booming GLP-1 injectable drugs is up 29% so far this year.

Post cover
Image courtesy of "The Wall Street Journal"

Stock Market Today: What to Watch (The Wall Street Journal)

Shell (SHEL, NL: SHELL): The energy giant launched a $3.5 billion share buyback program and said that its third-quarter earnings rose on [higher refining ...

Post cover
Image courtesy of "Yahoo Finance"

Novo Nordisk: obesity drugs priority over century-old focus on insulin (Yahoo Finance)

Novo Nordisk said on Thursday treating obesity with its weight-loss drug Wegovy as a precursor to type 2 diabetes was a priority for the company, ...

Novo Nordisk: Q3 Earnings Snapshot (The Advocate)

BAGSVAERD, Denmark (AP) — BAGSVAERD, Denmark (AP) — Novo Nordisk A/S (NVO) on Thursday reported third-quarter net income of $3.28 billion.

Post cover
Image courtesy of "Bloomberg"

Novo Nordisk's Earnings Surge on Frenzy for Obesity Drugs (Bloomberg)

Novo Nordisk A/S sales surged in the third quarter as demand continued unabated for its obesity and diabetes blockbusters.

Post cover
Image courtesy of "CNBC"

Weight-loss drug Wegovy could get expanded FDA approval within ... (CNBC)

Novo Nordisk said its blockbuster weight-loss drug Wegovy could receive expanded approval from the U.S. Food and Drug Administration within six months.

Post cover
Image courtesy of "Fortune"

Brands like Walmart and Nestle are right to worry about Wegovy ... (Fortune)

If food suppliers weren't already spooked by the surge in demand for weight loss-aiding drugs like Wegovy and Ozempic, they've just been given a fresh $900 ...

Post cover
Image courtesy of "Morningstar.com"

Novo Nordisk Earnings Continue to Surge on Blockbuster Weight ... (Morningstar.com)

Novo Nordisk's earnings soared by 56% in the third quarter, boosted by blockbuster weight-loss drugs that have quickly made the Danish drugmaker Europe's most ...

Novo Nordisk manages expectations for big M&A deals as diabetes ... (Endpoints News)

As Novo Nordisk counts a surge in sales, thanks in large part to its obesity and diabetes franchises, the Danish drugmaker has its checkbook out for deals.

Post cover
Image courtesy of "Investor's Business Daily"

Novo Nordisk Stock Jumps As Wegovy Sales Skyrocket 734 ... (Investor's Business Daily)

Adjusted profit came out 5.02 Danish krone per share — about 72 cents a share. Earnings grew 57% and topped expectations for 4.70 Danish krone. Sales of weight- ...

Post cover
Image courtesy of "STAT"

Novo Nordisk is concluding research on Wegovy's impact on ... (STAT)

Good morning, all. Damian here with a look at the future of treating Duchenne muscular dystrophy, the departure of an influential biotech CEO, and the next ...

Explore the last week